Displaying 101 - 120 of 853
| Active Ingredient | LAMIVUDINE |
| Therapeutic Class | NRTI |
| Indications | A combination of oral lamivudine and oral zidovudine has p roduced significant and sustained increases in CD4+ counts and decreases in viral load in HIV-infected patients. Lamivudine is indicated for More ... |
| Caution | Diarrhoea, headache, fatigue, insomnia, arthralgias, myalgias, neuropathy, nasal signs and symptoms, elevated liver enzymes, skin rash, fever or chills, ear, nose and throat infections. Concurrent use More ... |
| Dose Range |
Adult: 150mg orally twice daily , or 300mg once daily . Pediatric 3 months - 16 years: 4mg/kg twice daily (up to a maximum dose of 150mg twice a day ). Chronic hep atitis B: 100mg orally daily for adults and 3mg/kg once daily (maximum daily dose = |
| Drug Interactions | |
| Pregnancy | The animal and human data suggest that lamivudine is a low risk to the developin More ... |
| Breast Feeding | Lamivudine is distributed into milk in humans. It is not known whether the drug More ... |
| Active Ingredient | STAVUDINE |
| Therapeutic Class | NRTI |
| Indications | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine p er tablet). Not recommended in children under 12 y ears. |
| Caution | Peripheral neuropathy , serum transaminase elevations, lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported. Concurrent administration of stavudine an More ... |
| Dose Range |
Adult greater than 60kg: 40mg every 12 hours and less than 60kg: 30mg every 12 hours. Pediatric: birth to 13 days: 0.5 mg/kg every 12 hours. 14 days and older: 1 mg/kg every 12 hours and weighing less than 30 kg. May be taken without regard to meals. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ZIDOVUDINE |
| Therapeutic Class | NRTI |
| Indications | In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, la More ... |
| Caution | Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincrist More ... |
| Dose Range | Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR | LAMIVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection in combination with other antiretrovirals. |
| Caution | As for abacavir and lamivudine. |
| Dose Range | Adult:40 kg and over One tablet once daily . Abacavir/Lamivudine can be taken with or without food. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATAZANAVIR | RITONAVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Ritonavir-Although the limited human data do not allow a better assessment of th More ... |
| Breast Feeding | Ritonavir-No reports describing the use of ritonavir during lactation have been More ... |
| Active Ingredient | BICTEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection. |
| Caution | Patients with HIV-1 infection should be tested for the presence of chronic hepatitis B virus (HBV) before initiating antiretroviral therapy (ART)Lactic acidosis and severe hepatomegaly with steatosis, More ... |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | COBICSTAT | ELVITEGRAVIR | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV Infection |
| Caution | Appetite decreased; asthenia; constipation; diarrhoea; dizziness; electrolyte imbalance; flatulence; gastrointestinal discomfort; headache; hyperbilirubinaemia; hyperglycaemia; hypersensitivity; hyper More ... |
| Dose Range | 1 tablet once daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EFAVIRENZ | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection |
| Caution | Lactic acidosis and severe hep atomegaly with steatosis, including fatal cases, have been rep orted with the use of nucleoside analogues in combination with other antiretrovirals. |
| Dose Range | One tablet once daily on an empty stomach; not recommended for pediatric patients younger than 18 years. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMTRICITABINE | TENOFOVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications |
Indicated in combination ,with other antiretroviral agents (ARTs) for treatment of HIV-1 infection in adults. HIV-1 Pre-exposure Prophylaxis Indicated for at-risk patients to reduce risk of HIV-1 More ... |
| Caution | Lactic acidosis and severe hepatomegaly with steatosis. Emtricitabine/tenofovir should not be used as part of a triple nucleoside regimen. Emtricitabine/ tenofovir should not be coadministered with it More ... |
| Dose Range | One tablet once daily with or without food; not recommended for pediatric patients younger than 18 years |
| Drug Interactions | Concomitant use of emtricitabine/tenofovir DF (FTC/TDF) with certain drugs may result in known or potentially clinically important drug interactions, some of which may increase plasma concentrations o More ... |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LAMIVUDINE | ZIDOVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | Indicated in combination with other antiretroviral agents for the treatment of HIV infection. |
| Caution | Headache, fatigue, nausea, vomiting, diarrhoea, neutropenia, anemia, neuropathy , insomnia, nasal symptoms and musculoskeletal pain. |
| Dose Range | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine per tablet). Not recommended in children under 12 y ears. |
| Drug Interactions | |
| Pregnancy | The incidence and clinical significance of mitochondrial dysfunction after in ut More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LOPINAVIR | RITONAVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications |
In combination with other antiretrovirals for the treatment of HIV- infection. |
| Caution | Headache, fatigue, diarrhoea and nausea. Increased blood lipids and infrequent cases of pancreatitis have been reported. As with other protease inhibitors, Lipodystrophy syndrome (i.e., increased More ... |
| Dose Range |
Adults and Pediatric12 years and older: Lopinavir 400/100 millgrams (mg) (lopinavir/ritonavir, respectively) twice daily taken with food. A dose increase to 533/133 mg twice daily is recommended whe lopinavir/ritonavir is taken concomitantly with e |
| Drug Interactions | |
| Pregnancy | Avoid oral solution due to high alcohol and propylene glycol content; use tablet More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | INTERFERON ALPHA 2B |
| Therapeutic Class | INTERFERONS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INTERFERON BETA 1A |
| Therapeutic Class | INTERFERONS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | INTERFERON BETA 1B |
| Therapeutic Class | INTERFERONS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ACYCLOVIR |
| Therapeutic Class | NUCLEOSIDES AND NUCLEOTIDES |
| Indications |
Effective in treating initial or recurrent herp es simplex virus, herp es zoster and varicella zoster virus infections. |
| Caution | Acyclovir is generally well tolerated. GI disturbances, renal failure, local reactions at the injection site, headache and rash may occur. A finger cot or rubber glove should be utilized for ap p More ... |
| Dose Range | Adult: For the treatment of initial genital herp es: 200mg orally 5 times daily for 7-10 days. For the treatment of herpes zoster: 800mg orally 5 times daily . For chronic suppressive therapy for recurrent diseases 400mg twice daily (or 200 |
| Drug Interactions | |
| Pregnancy |
With systemic use: Not known to be harmful—manufacturers advise use only when p More ... |
| Breast Feeding |
With systemic use: Significant amount in milk after systemic administration—not More ... |
| Active Ingredient | VALACYCLOVIR |
| Therapeutic Class | NUCLEOSIDES AND NUCLEOTIDES |
| Indications | .Effective in treating initial or recurrent herpes simplex virus, herpes zoster and varicella zoster virus infections |
| Caution |
Valacyclovir is generally well tolerated. GI disturbances, nausea, abdominal pain, renal failure, local reactions at the injection site, headache and rash may occur. A finger cot or rubber glove sho More ... |
| Dose Range | Herpes zoster: 1g 3 times daily for 7 day s; Herp es simp lex: 500 mg twice daily for 3 to 5 day s for recurrent ep isodes or for up to 10 day s for a first ep isode. Treatment should be started as soon as sy mp toms occur; ideally within 48 to 72 hours. |
| Drug Interactions | |
| Pregnancy | Not known to be harmful—manufacturers advise use only when potential benefit out More ... |
| Breast Feeding | Significant amount in milk after systemic administration—not known to be harmful More ... |
| Active Ingredient | ANTIPROTOZOALS |
| Therapeutic Class | ANTIPROTOZOALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ARTESUNATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be f More ... |
| Caution | Gastrointestinal disturbances, pruritus and rash, dizziness, headache, tinnitus, neutropenia, elevated liver enzyme values, and ECG abnormalties including prolongation of the QT interval. |
| Dose Range | Oral: 4 mg/kg once daily , for 3 days. IM or IV: 2.4 mg/kg repeated after 12 and 24 hours and then once daily thereafter, transferring to an appropriate oral regimen after at least 24 hours. |
| Drug Interactions | |
| Pregnancy | Severe or complicated falciparum malaria is associated with a high risk of fatal More ... |
| Breast Feeding |
| Active Ingredient | CHLOROQUINE PHOSPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Acute and prophylactic treatment of malaria. Active rheumatoid arthritis and Systemic and discoid lupus erythematosus |
| Caution | For prophylaxis, drug should be taken on the same day each week. Nausea, vomiting, abdominal cramps, blurred vision. caution is recommended in patients with risk factors for cardiac events and th More ... |
| Dose Range | 1g to start, 500mg in 6 hours and 500mg daily for 2 days. Prophylaxis: 500mg per week, 1 week before exposure and continuing throughout and for 4 week after exposure. |
| Drug Interactions |
Avoid taking an antacid or Kaopectate (kaolin-pectin) within 4 hours before or 4 hours after chloroquine. Avoid alcohol. |
| Pregnancy | Benefit of use in prophylaxis and treatment in malaria outweighs risk. |
| Breast Feeding | Present in breast milk and breast-feeding should be avoided when used to treat r More ... |
| Active Ingredient | CHLOROQUINE SULPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |